Research Article

The Associations of Novel Vitamin D₃ Metabolic Gene CYP27A1 Polymorphism, Adiponectin/Leptin Ratio, and Metabolic Syndrome in Middle-Aged Taiwanese Males

Kai-Hung Cheng, Edward Hsi, Chia-Chu Liu, Chun-Nung Huang, Yung-Chin Lee, Chih-Sheng Chu, Bo-Ying Bao, Chu-Fen Chang, Shu-Pin Huang, Po-Lin Kuo, and Wen-Ter Lai

1 Division of Cardiology, Department of Internal Medicine, Kaohsiung Medical University Hospital, 100 Tzyou 1st Road, Kaohsiung 80708, Taiwan
2 Faculty of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 80708, Taiwan
3 Graduate Institute of Medicine, Kaohsiung Medical University, Kaohsiung 80708, Taiwan
4 Department of Medical Research, Kaohsiung Medical University Hospital, Kaohsiung 80708, Taiwan
5 Department of Urology, Kaohsiung Medical University Hospital, 100 Tzyou 1st Road, Kaohsiung 80708, Taiwan
6 Department of Urology, College of Medicine, Kaohsiung Medical University, Kaohsiung 80708, Taiwan
7 Pingtung Hospital, Department of Health, Executive Yuan, Pingtung 90804, Taiwan
8 Department of Pharmacy, China Medical University, Taichung 40402, Taiwan
9 Department of Physical Therapy, Tzu Chi University, Hualien 97004, Taiwan
10 Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 80708, Taiwan

Correspondence should be addressed to Shu-Pin Huang; shpihu@yahoo.com.tw and Wen-Ter Lai; wtlaic@cc.kmu.edu.tw

Received 1 May 2014; Revised 8 December 2014; Accepted 11 December 2014

Copyright © 2015 Kai-Hung Cheng et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Metabolic syndrome (MetS) confers increased risks of cardiovascular disease (CVD). Both vitamin D₃ and adipocytokines (especially adiponectin and leptin) have a great impact on CVD and MetS. In vitamin D₃ metabolism, the vitamin D₃ 25-hydroxylase (CYP27A1) and 25-hydroxyvitamin D₃ 1-alpha-hydroxylase (CYP27B1) are two key enzymes. This study aimed to examine the influence of vitamin D₃ CYP27 single nucleotide polymorphisms (SNPs) on adipocytokines and MetS. Cross-sectional data and DNA samples were collected from male volunteers (n = 649, age: 55.7 ± 4.7 years). Two tagging SNPs, CYP27A1 rs4674344 and CYP27B1 rs10877012, were selected from the HapMap project. MetS was significantly associated with the CYP27A1 rs4674344 SNP, appearing to be significantly lower in T-carriers than in AA subjects (3.7 ± 4.0 versus 5.1 ± 6.0, P = 0.001) and significantly negatively associated after adjustment. For each MetS component associated with the CYP27A1 rs4674344 SNP, the A/L ratios were significantly negative in preclinical stage (condition not meeting the individual criteria), except the blood pressure. In conclusion, CYP27A1 rs4674344 SNP, A/L ratio, and MetS are significantly associated and T-carriers might have a higher risk of developing MetS due to low A/L ratios in the preclinical stage.

1. Introduction

Metabolic syndrome (MetS), a collection of cardiometabolic risk factors that includes obesity, insulin resistance, hypertension, and dyslipidemia, confers increased risks of coronary heart disease and cardiovascular disease (CVD) [1–5]. In terms of mechanism, both adipocytokine and vitamin D are highly associated with MetS.

Among the adipocytokines, the relationships between adiponectin and leptin with MetS are the best established
2. Material and Methods

2.1. Study Population and Protocol. In this cross-sectional study, 694 Taiwanese males (age: 44–77 years) living in Kaohsiung City were recruited from a free health screening program held by our institution [1, 32]. Each of them participated with informed written consent. Ethical approval following the Declaration of Helsinki was authorized by the Institutional Research Ethics Committee of Kaohsiung Medical University Hospital.

The men who had a previous diagnosis of hypertension, diabetes mellitus (DM), or hyperlipidemia controlled by regular medication were included in this study, but those who were diagnosed with labile hypertension, labile DM, and advanced liver and/or renal disease were excluded. Entire records of medical, surgical, and psychosexual history, as well as the results of physical examinations including measurements of body weight, height, and blood pressure for each participant, were collected (Figure 1).
The subjects were classified as alcohol drinkers, cigarette smokers, or betel nut chewers if they had regularly consumed any alcoholic beverage ≥1 time per week, smoked ≥10 cigarettes per week, or chewed ≥7 betel quids per week for at least the last 6 months [33, 34]. Hypertension was defined as a systolic blood pressure of ≥140 mmHg or diastolic blood pressure of ≥90 mmHg. Hyperlipidemia was defined as a total cholesterol level of ≥200 mg/dL or triglyceride level of ≥200 mg/dL. [1, 35]. DM was diagnosed when the fasting blood glucose (FBG) was ≥126 mg/dL.

2.2. Diagnosis of Metabolic Syndrome (MetS). In accordance with the modified criteria proposed by the Bureau of Health Promotion in Taiwan, MetS was diagnosed once meeting at least three of the following criteria: (1) waist circumference (WC) ≥90 cm; (2) triglycerides (TG) ≥150 mg/dL; (3) high density lipoprotein (HDL) cholesterol <40 mg/dL; (4) blood pressure (BP) ≥130/85 mmHg or current use of antihypertensive medications; (5) FBG >100 mg/dL, previously diagnosed as DM, or current use of oral hypoglycemic agents or insulin [1, 5, 36].

2.3. Biochemical Analysis Using Radioimmunoassay. For further biochemical analysis and hormone profiling, each peripheral venous blood sample was drawn after more than 8 hours of fasting overnight into pyrogen-free tube. Diasorin radioimmunoassay kits (Northwestern Avenue Stilwater, USA; intra-assay CV: 6.8%~11.3%; interassay CV: 12.3%~15.3%) were used to determine the expression of glucose (Glu), insulin (INS), CRP, adiponectin, leptin, and T3. The Millipore radioimmunoassay kits (Missouri, USA) were used to measure the leptin and adiponectin (intra-assay CV: 3.4%~8.3% and 1.78%~6.21%, resp.; interassay CV: 3.0%~6.2% and 6.90%~9.25%, resp.).

2.4. Selection, Identification, and Genotyping of the Single Nucleotide Polymorphism. Tag single nucleotide polymorphisms (SNPs) were selected by searching data on Han Chinese in the HapMap project (http://www.hapmap.org/) using Haplovew software [37]. Afterward the tag SNPs were identified by the following criteria: (1) SNPs located in the CYP27A1 and CYP27B1 genes or within the flanking 5 kb regions; (2) a minor allele frequency of ≥0.10; and (3) other unselected SNPs that could be captured by one of the tag SNPs with a linkage disequilibrium of $r^2$ ≥ 0.80. Selection of SNPs had been completed in March 2006, and only 1 tag SNP had been identified for each of the CYP27A1 and CYP27B1 genes, namely, rs4675344 on the intron 1 region and rs10877012 on the promoter region (Figure 1).

DNA was extracted from the peripheral whole blood using a Puregen DNA Isolation Kit (Genta Systems Inc., Minneapolis, MN). The two SNPs were determined using a TaqMan 5’ allelic discrimination assay performed on an assays-on-demand SNP genotyping kit (Applied Biosystems, Foster City, CA). SNP amplification assays including 10 ng of sample DNA in 25 μL of reaction solution contained in 12.5 μL of 2X TaqMan Universal PCR Mix (Applied Biosystems) and 1.25 μL of predeveloped assay reagent from the SNP genotyping product (Applied Biosystems) contained in two primers and two MGB-TaqMan probes were performed according to the manufacturer’s instructions. Reaction conditions consisted of preincubation at 50° C for 2 min and 95° C for 10 min, followed by 40 cycles at 92° C for 15 s and 60° C for 1 min. Amplifications were performed in an ABI Prism 7500 Sequence Detection System (Applied Biosystems). Our genotyping results were also validated in accordance with the identical results from the 25 patients and 25 controls (about 10% of our participants) who were randomly selected for regenotyping by direct sequencing.

2.5. Statistical Analysis. The demographic and laboratory data are presented as mean ± standard deviation (SD). For the controls, the Hardy-Weinberg equilibrium was checked using the chi-square test. The categorical variables and continuous variables were examined by the contingency tables (Pearson chi-square test) and the Student's t-test, respectively. Linkage disequilibrium between the polymorphisms was assessed via Haplovew software [37]. The ANCOVA test was used to evaluate the associations between the CYP27A1 rs4675344 and adiponectin/leptin ratio (A/L ratio) controlling for other covariates. Multiple linear regression analysis was used to examine the associations between the A/L ratio and MetS score for the CYP27A1 rs4675344. Since the established cardiovascular risk factors including hypertension and DM are the components of MetS, we were only adjusted for sex, age, coronary artery disease (CAD), stroke, alcohol consumption, and smoking status. We also studied the effects of the individual MetS component. All statistical analyses were performed by SPSS 18.0 software (Chicago, IL, USA) with significance levels of $\alpha = 0.05$.

3. Results

3.1. Patient Characteristics. The baseline characteristics and biochemical data of our subjects with respect to CYP27A1 rs4675344 were summarized in Table 1. A total of 649 patients had adequate qualities for analysis, of whom 447 (68.9%), 179 (27.6%), and 23 (3.5%) patients had the AA, AT, and TT genotypes, respectively. Due to the low minor allele frequency, the patients with TT and patients with AT were united into the T-carriers for analysis. Compared with the patients with the AA genotype, the T-carriers had significantly higher WC (87.1 ± 6.9 versus 85.7 ± 7.2 cm, $P = 0.003$), positive history of dyslipidemia, total and HDL cholesterol (4.3 ± 1.0 versus 4.1 ± 1.0, $P = 0.006$), leptin (6.5 ± 28.2 versus 4.0 ± 3.3, $P = 0.005$), and A/L ratio (3.7 ± 4.0 versus 5.1 ± 6.0, $P = 0.001$). The T-carriers showed nominal significant number of MetS components (2.1 ± 1.4 versus 1.9 ± 1.4, $P = 0.04$), lower HDL (46.5 ± 11.3 versus 48.5 ± 11.0 mg/dL, $P = 0.04$), adiponectin (10.9 ± 6.2 versus 12.1 ± 7.2 ng/mL, $P = 0.03$), and increased number of MetS components and greater percentages of each MetS component were also noted in the T-carriers compared to those with the AA genotype (Table 2). However, no significant associations were found in the CYP27BI rs10877012 SNP.

3.2. Regression Analysis of the CYP27A1 rs4675344 SNP against Other Study Parameters for A/L Ratio. Four models were established for our regression analysis, namely, Model 1
Table 1: Means ± standard deviations or numbers (%) of the baseline characteristics and biochemical variables in the patients with the CYP27A1 rs4674344 SNP.

|                      | Subjects with AA (n = 447) | Subjects with T-carrier (n = 202) | P value |
|----------------------|----------------------------|----------------------------------|---------|
| Age (yr)             | 55.5 ± 4.1                 | 56.1 ± 5.1                       | 0.11    |
| BMI (kg/m²)          | 25.6 ± 7.1                 | 25.6 ± 2.9                       | 0.93    |
| Waist circumference (cm) | 85.7 ± 7.2               | 87.1 ± 6.9                       | 0.03*   |
| Hip circumference (cm) | 100.4 ± 64.5              | 97.8 ± 5.5                       | 0.57    |
| SBP (mm-Hg)          | 130.9 ± 12.4               | 130.5 ± 11.1                     | 0.75    |
| DBP (mm-Hg)          | 82.1 ± 8.6                 | 82.3 ± 8.7                       | 0.86    |
| DM, n (%)            | 4.2 (9.4)                  | 27 (13.4)                        | 0.14    |
| Hypertension, n (%)  | 124 (27.7)                 | 66 (32.7)                        | 0.20    |
| Smoking, n (%)       | Nonsmokers 331 (74.0)      | 140 (69.3)                       | 0.36    |
|                      | Former Smokers 62 (13.9)   | 30 (14.9)                        |         |
|                      | Current Smokers 54 (12.1)  | 32 (15.8)                        |         |
| Dyslipidemia history, n (%) | 76 (16.8)            | 53 (26.2)                        | 0.006*  |
| CAD history, n (%)   | 30 (6.7)                   | 15 (7.4)                         | 0.76    |
| Stroke history, n (%)| 3 (0.7)                    | 5 (2.5)                          | 0.056   |
| Betel quid, n (%)    | 2 (0.4)                    | 1 (0.5)                          | 0.87    |

Blood biochemistry

|                      | Subjects with AA (n = 447) | Subjects with T-carrier (n = 202) | P value |
|----------------------|----------------------------|----------------------------------|---------|
| Fasting glucose (mg/dL) | 99.6 ± 20.6            | 101.2 ± 22.2                     | 0.36    |
| Triglycerides (mg/L)  | 134.1 ± 98.6             | 137.7 ± 88.8                     | 0.66    |
| Total cholesterol (mg/dl) | 188.6 ± 33.4           | 191.9 ± 35.8                     | 0.25    |
| HDL-C (mg/dL)         | 48.5 ± 11.0              | 46.5 ± 11.3                      | 0.04*   |
| CHOL(T)/HDL           | 4.1 ± 1.0                | 4.3 ± 1.0                        | 0.006*  |
| Adiponectin (ng/mL)   | 12.1 ± 7.2               | 10.9 ± 6.2                       | 0.03*   |
| Leptin (ng/mL)        | 4.0 ± 3.3                | 6.5 ± 28.2                       | 0.005*  |
| Adiponectin/leptin    | 5.1 ± 6.0                | 3.7 ± 4.0                        | 0.001*  |
| 1,25(OH)2D3 (pg/mL)   | 45.6 ± 19.0              | 43.3 ± 17.2                      | 0.14    |

BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; DM: diabetes mellitus; CAD: coronary artery disease; CHOL(T): total cholesterol; HDL: high density lipoprotein. * Significant difference (P < 0.05).

that was adjusted for baseline characteristics including age, BMI, WC, hip circumference, systolic blood pressure, and diastolic blood pressure; Model 2 was then adjusted for exsmoker, current smoker, ex-betel nut chewer, current betel nut chewer, exdrinker, and current drinker; Model 3 that was further adjusted for comorbidities including DM, hypertension, dyslipidemia, CAD, and stroke; and Model 4 that was farther adjusted for biochemistry data including fasting glucose, total cholesterol, low density lipoprotein (LDL), HDL, and triglycerides (TG). Negative associations between the CYP27A1 rs4675344 SNP and the A/L ratio were found consistently from Model 1 to Model 4. In addition, obesity and the parameters related to MetS, including BMI and WC, were also negatively related to the A/L ratio. In Model 4, LDL and fasting glucose were also significantly, negatively associated with the A/L ratio (Table 3).

3.3. Associations between the Components of the MetS and CYP27A1 rs4674344 for the A/L Ratio. The A/L ratio showed greatest association with the CYP27A1 rs4674344 SNP, and the MetS also had significant association, too. Therefore, we further examined the influence of MetS and its components on the associations between the CYP27A1 rs4674344 SNP and A/L ratio. Greater association between A/L ratio and the CYP27A1 rs4674344 SNP was noted in the low MetS score group when compared to the high MetS score group (Figure 2). Significant A/L ratio was only found when most of the MetS components were in the preclinical stage (not meeting individual criteria). However, there was no significant association with the BP component after adjusting for age, BMI, smoking, alcohol drinking, betel nut chewing, CAD, total cholesterol, LDL, HDL, and the other 4 components for the CYP27A1 rs4674344 SNP (Table 4, Figure 3).

4. Discussion

This study selected the SNPs by searching Han Chinese data from the HapMap project (http://www.hapmap.org/) using Haploview software [37]. These SNPs were located in the CYP27A1 genes and CYP27B1 genes or within the flanking 5 kb regions with a minor allele frequency ≥0.10. Accordingly, the other unselected SNPs could be captured by one of the tag SNPs with a linkage disequilibrium of $r^2 \geq 0.80$. As a result, only 1 tag SNP was obtained for each of the CYP27A1 and CYP27B1 genes, namely, the rs4675344 on intron 1 region and the rs10877012 on the promoter region (Figure 1).
Table 2: Means ± standard deviations or numbers (%) of the MetS parameters in the patients with the CYP27A1 rs4674344 SNP.

| MetS, n (%) | Subjects with AA (n = 447) | Subjects with T-carrier (n = 202) | P value of the association with CYP27A1 rs4674344 |
|-------------|----------------------------|----------------------------------|-----------------------------------------------|
| Yes         | 158 (35.4)                 | 90 (44.6)                        | 0.038*                                        |
| No          | 289 (64.6)                 | 112 (55.4)                       |                                               |
| Component numbers: |                   |                                  |                                               |
| 0 (n = 99)  | 78 (17.8)                  | 21 (10.4)                        |                                               |
| 1 (n = 171) | 113 (25.5)                 | 58 (28.7)                        |                                               |
| 2 (n = 129) | 96 (21.6)                  | 33 (16.3)                        |                                               |
| 3 (n = 142) | 90 (20.2)                  | 52 (25.7)                        |                                               |
| 4 (n = 83)  | 53 (11.9)                  | 30 (14.9)                        |                                               |
| 5 (n = 23)  | 15 (3.3)                   | 8 (4.0)                          |                                               |
| Number of MetS criteria | 1.9 ± 1.4                  | 2.1 ± 1.4                        | 0.038*                                        |

Individual MetS Component, n (%)

| Component                           | Subjects with AA | Subjects with T-carrier | P value |
|-------------------------------------|------------------|-------------------------|---------|
| High waist circumference            | 118 (26.3)       | 65 (32.1)               | 0.26    |
| High blood pressure                 | 273 (61.1)       | 127 (62.9)              | 0.38    |
| Low HDL                             | 95 (21.2)        | 55 (27.2)               | 0.25    |
| High triglyceride                   | 150 (33.6)       | 85 (42.1)               | 0.06    |
| High fasting glucose                | 160 (35.8)       | 79 (39.1)               | 0.51    |

MetS: metabolic syndrome; HDL: high density lipoprotein; P values were adjusted for age, alcohol, smoking and betel chewing. * Significant difference (P < 0.05).

The MetS and its HDL component are significantly associated with the CYP27A1 rs4674344 SNP. CYP27A1 mRNA expression is also significantly associated with MetS in one in vivo study [38]. The HDL cholesterol has been reported to have a strong correlation with the adiponectin and to affect the adipocyte metabolism and adiponectin expression [39, 40]. And it is known that mutations in CYP27A1 are associated with cerebrotendinous xanthomatosis, a rare lipid storage disease with the deposition of a form of cholesterol (cholestanol) in the brain and other tissues [41–44]. Our study provides further novel information of the impact of CYP27A1 rs4674344 SNP on both of them. However, like previous document, no CYP27 SNPs in our study were associated with 1,25(OH)(2)D levels [45].

A/L ratio is the best surrogate for inflammatory burden and insulin resistance [46, 47]. Adiponectin acts as an insulin-sensitizing adipocytokine and an anti-inflammatory factor especially with regard to atherosclerosis [48]. Leptin is known to be a satiety factor regulating body weight by suppressing appetite and stimulating energy expenditure. Leptin is also a proinflammatory adipocytokine, which induces the development of T helper 1 cells that contribute to the progress of inflammation [49–51]. For in-depth analysis in our study, A/L ratio was not only significantly higher in the CYP27A1 rs4674344 SNP T-carriers than in those with the AA genotype (3.7 ± 4.0 versus 5.1 ± 6.0, P = 0.001), but was also most correlated with this SNP. Against other study parameters for the A/L ratio, the CYP27A1 rs4675344 SNP consistently had significantly negative association with the A/L ratio from Model 1 to Model 4 after adjusting for baseline characteristics, life habits, comorbidities, and biochemistry profiles. In addition, obesity and MetS-related parameters including BMI, WC, and hip circumference were also negatively associated with the A/L ratio. In Model 4, LDL and fasting glucose were significantly negatively associated with the A/L ratio, too (Table 3). These results all indicated that the CYP27A1 rs4675344 SNP, A/L ratio, and MetS are closely associated with each other.

Another set of novel in-depth information provided by our study related to the CYP27A1 rs4674344 SNP was that the A/L ratio was only significantly different in the preclinical stage of most individual MetS criteria, except for the BP component, but not in the clinical stage of MetS. The SNPs of genes are imprinted in the germ-cell stage and one previous investigation had also reported that the changes of A/L ratio and development of the MetS partly accorded with one's own genetics [52]. Therefore, our novel findings indicated that those T-carriers with the CYP27A1 rs4674344 SNP tend to have a higher risk of developing MetS, owing to an adipocytokine imbalance. However, the CYP27A1 rs4674344 SNP did not seem to play a role in the development of BP component.

Based on our findings and the previous evidence, the CYP27A1 rs4674344 might participate in lipid and adipocytokine homeostasis and in the crosstalk of HDL with adiponectin. However, unequal number of subjects with the polymorphism of CYP27A1 rs4674344 was the main limitation in this study, which might lead to bias in the results. A large-scale cohort study with equal numbers of subjects may be dedicated to investigate the refined causality,
Table 3: $\beta$ coefficients between the CYP27A1 rs4674344 SNP and the adiponectin/leptin ratio.

|                    | Model 1       | Model 2       | Model 3       | Model 4       |
|--------------------|---------------|---------------|---------------|---------------|
| $\beta$ coefficient| $P$ value     | $\beta$ coefficient | $P$ value     | $\beta$ coefficient | $P$ value     |
| CYP27A1rs4674344   | $-0.58$ | $0.0092^*$ | $-0.6$ | $0.0077^*$ | $-0.57$ | $0.0158^*$ | $-0.51$ | $0.0257^*$ |
| Age                | 0.03  | 0.6655      | 0.03  | 0.6287      | 0.05  | 0.4556      | 0.06  | 0.3401      |
| BMI                | $-0.51$ | $0.0001^*$ | $-0.51$ | $0.0002^*$ | $-0.51$ | $0.0005^*$ | $-0.36$ | $0.0108^*$ |
| WC                 | $-0.39$ | $<0.0001^*$ | $-0.38$ | $<0.0001^*$ | $-0.38$ | $<0.0001^*$ | $-0.3$ | $<0.0001^*$ |
| HC                 | 0.23  | 0.0006      | 0.22  | 0.0010      | 0.21  | 0.0026      | 0.14  | 0.0493      |
| SBP                | $-0.08$ | 0.0513      | $-0.08$ | 0.0399      | $-0.08$ | 0.0638      | $-0.05$ | 0.1762      |
| DBP                | 0.02  | 0.4605      | 0.02  | 0.5053      | 0.02  | 0.4651      | 0.02  | 0.4403      |
| Ex-smoker          | $-0.54$ | 0.2496      | $-0.44$ | 0.3763      | $-0.33$ | 0.4908      |
| Current smoker     | 0.31  | 0.4731      | 0.18  | 0.6967      | 0.15  | 0.729       |
| Ex-betel nut chewer| $-0.02$ | 0.9961      | $-0.21$ | 0.9507      | $-0.16$ | 0.9597      |
| Current betel nut chewer | $-0.05$ | 0.9776 | 0.22 | 0.907 | 0.34 | 0.853 |
| Ex-drinker         | $-0.28$ | 0.6513      | 1.39  | 0.2231      | 1.35  | 0.2198      |
| Current drinker    | 0.96  | 0.3427      | 0.24  | 0.6799      | 0.21  | 0.6329      |
| DM                 | $-0.17$ | 0.7559      | 0.02  | 0.9296      |
| Hypertension       | $-0.09$ | 0.0887      | $-0.14$ | 0.6479      |
| Dyslipidemia       | $-0.5$  | 0.2821      | $-0.34$ | 0.4727      |
| CAD                | $-0.53$ | 0.3797      | $-2.12$ | 0.3933      |
| Stroke             | $-2.27$ | 0.702       | 0.0414* |
| Fasting glucose    | $-2.73$ | 0.0125* |
| Chol(T)            | 14.3  | 0.2066      |
| LDL                | $-13.04$ | 0.0033      |
| HDL                | 4.25  | 0.5984      |
| TG                 | $-7.73$ | 0.0003      |

Model 1: adjusted for baseline characteristics, including age, BMI (body-mass index), WC (waist circumference), HC (hip circumference), SBP (systolic blood pressure) and DBP (diastolic blood pressure); Model 2: further adjusted for habits, including ex-smoker, current smoker, ex-betel nut chewer, current betel nut chewer, ex-drinker and current drinker; Model 3: further adjusted for co-morbidities, including DM (diabetes mellitus), hypertension, dyslipidemia, CAD (coronary artery disease) and stroke; Model 4: further adjusted for biochemistry data, including fasting glucose, CHOL(T) (total cholesterol), LDL (low density lipoprotein), HDL (high density lipoprotein) and TG (triglycerides). *Significant difference ($P < 0.05$).

Figure 2: Associations of the adiponectin/leptin ratio with the metabolic syndrome (MetS) scores. The association between adiponectin/leptin ratio and the CYP27A1 rs4674344 SNP was more significant in the group with low MetS score than in the group with high MetS score.
Table 4: Associations between the CYP27A1 rs4674344 SNP and each component of the metabolic syndrome for the adiponectin/leptin ratio.

|                      | MetS | WC 90 cm | High BP | Low HDL | High TG | High FBG |
|----------------------|------|----------|---------|---------|---------|----------|
| A/L ratio            |      |          |         |         |         |          |
| AA genotype          | 6.80 ± 0.40 | 1.97 ± 0.16 | 6.16 ± 0.36 | 1.70 ± 0.14 | 6.92 ± 0.60 | 4.14 ± 0.29 |
| T carrier            | 5.28 ± 0.43 | 1.68 ± 0.17 | 4.55 ± 0.36 | 1.45 ± 0.13 | 4.65 ± 0.60 | 3.28 ± 0.30 |
| P value              | 0.0287*   | 0.3269    | 0.0451   | 0.0818   | 0.2437   | 0.1344   |

The model was adjusted for age, BMI, smoking, alcohol drinking, betel nut chewing, CAD, total cholesterol, LDL, Chol(T)/HDL and the other 4 components, respectively, for the CYP27A1 rs4674344 SNP. A/L ratio: adiponectin/leptin ratio; MetS: metabolic syndrome; WC: waist circumference; BP: blood pressure; HDL: high density lipoprotein; TG: triglycerides; FBG: fasting blood glucose; BMI: body mass index; CHOL(T): total cholesterol. * Significant difference in MetS (P < 0.05); significant difference in 5 MetS component (P < 0.01).
including the SNP of CYP27A1 rs4674344 for the major cardiovascular events. In vitro studies may also be needed to clarify the comprehensive role of the CYP27A1 rs4674344 SNP.

5. Conclusions
This study reported the novel finding that vitamin D₃ metabolism gene CYP27A1 rs4674344 was closely associated
with A/L ratio and MetS. The A/L ratio alone had significant association with the CYP27A1 rs4675344 SNP. In addition, for the CYP27A1 rs4674344 SNP, the A/L ratio was only significantly different in the preclinical stage of the most individual MetS criteria except the BP component. This finding indicated that the T-carriers were at a higher risk of developing MetS.

**Conflict of Interests**

The authors declare that they have no conflict of interests which could be construed as influencing the position presented in, or the view of, the paper.

**Acknowledgments**

This work was supported by the Taiwan National Science Council (NSC 99–2314–B–037–035–Y3, NSC 98–2314–B–037–030–MY3, and NSC 99–2314–B–037–022–MY3), Kaohsiung Medical University Hospital (KMUH97–7R2, KMUH98–8R09, and KMUH98–8R10), and Kaohsiung Municipal Hsiao-Kang Hospital (kmhk–98–004). The authors deeply appreciated the help from Ms. Chao-Shih Chen, Department of Urology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan, in data collection.

**References**

[1] Y. C. Lee, C. C. Liu, C. N. Huang et al., “The potential impact of metabolic syndrome on erectile dysfunction in aging Taiwanese males,” *The Journal of Sexual Medicine*, vol. 7, no. 9, pp. 3127–3134, 2010.

[2] H. N. Ginsberg and P. R. Maccallum, “The obesity, metabolic syndrome, and type 2 diabetes mellitus pandemic: part I. Increased cardiovascular disease risk and the importance of atherogenic dyslipidemia in persons with the metabolic syndrome and type 2 diabetes mellitus,” *Journal of the CardioMetabolic Syndrome*, vol. 4, no. 2, pp. 113–119, 2009.

[3] S. Malik and N. D. Wong, “Metabolic syndrome, cardiovascular risk and screening for subclinical atherosclerosis,” *Expert Review of Cardiovascular Therapy*, vol. 7, no. 3, pp. 273–280, 2009.

[4] P. L. Huang, “eNOS, metabolic syndrome and cardiovascular disease,” *Trends in Endocrinology and Metabolism*, vol. 20, no. 6, pp. 295–302, 2009.

[5] P. L. Huang, “A comprehensive definition for metabolic syndrome,” *Disease Models and Mechanisms*, vol. 2, no. 5–6, pp. 231–237, 2009.

[6] K.-H. Cheng, S.-P. Huang, C.-N. Huang et al., “The impact of estradiol and 1,25(OH)2D3 on metabolic syndrome in middle-aged Taiwanese males,” *PloS ONE*, vol. 8, no. 3, Article ID e60295, 2013.

[7] W. Koenig, N. Khuseinova, J. Baumert, C. Meisinger, and H. Löwel, “Serum concentrations of adiponectin and risk of type 2 diabetes mellitus and coronary heart disease in apparently healthy middle-aged men: results from the 18-year follow-up of a large cohort from southern Germany,” *Journal of the American College of Cardiology*, vol. 48, pp. 1369–1377, 2006.

[8] S. H. Han, M. J. Quon, J.-A. Kim, and K. K. Koh, “Adiponectin and Cardiovascular Disease: Response to Therapeutic Interventions,” *Journal of the American College of Cardiology*, vol. 49, no. 5, pp. 531–538, 2007.

[9] F. Otsuka, S. Sugiyama, S. Kojima et al., “Plasma adiponectin levels are associated with coronary lesion complexity in men with coronary artery disease,” *Journal of the American College of Cardiology*, vol. 48, no. 6, pp. 1155–1162, 2006.

[10] D. S. Frankel, R. S. Vasan, R. B. D’Agostino Sr. et al., “Resistant, adiponectin, and risk of heart failure. The Framingham Offspring Study,” *Journal of the American College of Cardiology*, vol. 53, no. 9, pp. 754–762, 2009.

[11] F. Ziemke and C. S. Mantzoros, “Adiponectin in insulin resistance: lessons from translational research,” *The American Journal of Clinical Nutrition*, vol. 91, no. 1, pp. 2585–2615, 2010.

[12] A. Barseghian, D. Gawande, and M. Bajaj, “Adiponectin and vulnerable atherosclerotic plaques,” *Journal of the American College of Cardiology*, vol. 57, no. 7, pp. 761–770, 2011.

[13] M. Yamaguchi and T. Murata, “Involvement of regucalcin in lipid metabolism and diabetes,” *Metabolism: Clinical and Experimental*, vol. 62, no. 8, pp. 1045–1051, 2013.

[14] R. Wolk, P. Berger, R. J. Lennon, E. S. Brilakis, B. D. Johnson, and V. K. Somers, “Plasma leptin and prognosis in patients with established coronary atherosclerosis,” *Journal of the American College of Cardiology*, vol. 44, no. 9, pp. 1819–1824, 2004.

[15] S. S. Martin, A. Qasim, and M. P. Reilly, “Leptin resistance: a possible interface of inflammation and metabolism in obesity-related cardiovascular disease,” *Journal of the American College of Cardiology*, vol. 52, no. 15, pp. 1201–1210, 2008.

[16] N. Sattar, G. Wannamethee, N. Sarwar et al., “Leptin and coronary heart disease: prospective study and systematic review,” *Journal of the American College of Cardiology*, vol. 53, no. 2, pp. 167–175, 2009.

[17] Y.-C. Liao, K.-W. Liang, W.-J. Lee et al., “Leptin to adiponectin ratio as a useful predictor for cardiac syndrome X,” *Biomarkers*, vol. 18, no. 1, pp. 44–50, 2013.

[18] L. J. Rasmussen-Torvik, C. L. Wassel, J. Ding et al., “Associations of body mass index and insulin resistance with leptin, adiponectin, and the leptin-to-adiponectin ratio across ethnic groups: the multi-ethnic study of atherosclerosis (MESA),” *Annals of Epidemiology*, vol. 22, no. 10, pp. 705–709, 2012.

[19] P. J. W. H. Kappelle, R. P. F. Dullaart, A. P. van Beek, H. L. Hillege, and V. K. Somers, “Plasma leptin and proinflammatory cytokines in coronary artery disease patients,” *European Journal of Vascular and Endovascular Surgery*, vol. 29, no. 4, pp. 293–297, 2005.

[20] K. Kotani and N. Sakane, “Leptin: adiponectin ratio and metabolic syndrome in the general Japanese population,” *The Journal of Clinical Endocrinology and Metabolism*, vol. 31, no. 3, pp. 162–166, 2011.

[21] C. H. Jung, E. J. Rhee, J. H. Choi et al., “The relationship of adiponectin/leptin ratio with homeostasis model assessment insulin resistance index and metabolic syndrome in apparently healthy Korean male adults,” *Korean Diabetes Journal*, vol. 34, no. 4, pp. 106–112, 2010.

[22] J. I. Botella-Carretero, F. Alvarez-Blasco, J. J. Villafruela, J. A. Balsa, C. Vázquez, and H. F. Escobar-Morreale, “Vitamin D deficiency is associated with the metabolic syndrome in morbid obesity,” *Clinical Nutrition*, vol. 26, no. 5, pp. 573–580, 2007.

[23] M. K. Kim, M. Kang, K. W. Oh et al., “The association of serum vitamin D level with presence of metabolic syndrome and type 2 diabetes mellitus in Korean population,” *Journal of the Korean Diabetes Association*, vol. 53, no. 3, pp. 330–338, 2011.

[24] L. Lu, Z. Yu, A. Fan et al., “Plasma 25-hydroxyvitamin D concentration and metabolic syndrome among middle-aged and elderly Chinese individuals,” *Diabetes Care*, vol. 32, no. 7, pp. 1278–1283, 2009.
S. V. Van Linthout, A. Foryst-Ludwig, F. Spillmann et al., "Impact of HDL on adipose tissue metabolism and adiponectin expression," Atherosclerosis, vol. 210, no. 2, pp. 438–444, 2010.

G. N. Gallus, M. T. Dotti, and A. Federico, "Clinical and molecular diagnosis of cerebrotendinous xanthomatosis with a review of the mutations in the CYP27A1 gene," Neurological Sciences, vol. 27, no. 2, pp. 143–149, 2006.

I. Björkhem and M. Hansson, "Cerebrotendinous xanthomatosis: an inborn error in bile acid synthesis with defined mutations but still a challenge," Biochemical and Biophysical Research Communications, vol. 396, no. 1, pp. 46–49, 2010.

G. Lorbeck, M. Lewinska, and D. Rozman, "Cytochrome P450s in the synthesis of cholesterol and bile acids—from mouse models to human diseases," FEBS Journal, vol. 279, no. 9, pp. 1516–1533, 2012.

I. Björkhem, "Cerebrotendinous xanthomatosis," Current Opinion in Lipidology, vol. 24, no. 4, pp. 283–287, 2013.

J. Ahn, D. Albanes, S. I. Berndt et al., "Vitamin D-related genes, serum vitamin D concentrations and prostate cancer risk," Carcinogenesis, vol. 30, no. 5, pp. 769–776, 2009.

J. M. Lee, S. R. Kim, S. J. Yoo, O. K. Hong, H. S. Son, and S.-A. Chang, "The relationship between adipokines, metabolic parameters and insulin resistance in patients with metabolic syndrome and type 2 diabetes," Journal of International Medical Research, vol. 37, no. 6, pp. 1803–1812, 2009.

D. M. Maahs, R. F. Hamman, R. D’Agostino Jr. et al., "The association between adiponectin/leptin ratio and diabetes type: the SEARCH for Diabetes in Youth Study," Journal of Pediatrics, vol. 155, no. 1, pp. 133–135, 2009.

A. Stofkova, "Leptin and adiponectin: From energy and metabolic balance to inflammation and autoimmunity," Endocrine Regulations, vol. 43, no. 4, pp. 157–168, 2009.

C. Proccaci, E. Jirillo, and G. Matarese, "Leptin as an immunomodulator," Molecular Aspects of Medicine, vol. 33, no. 1, pp. 35–45, 2012.

A. Batra, B. Okur, R. Glauben et al., "Leptin: a critical regulator of CD4+ T-cell polarization in vitro and in vivo," Endocrinology, vol. 151, no. 1, pp. 56–62, 2010.

N. Likuni, Q. L. K. Lam, L. Lu, G. Matarese, and A. La Cava, "Leptin and inflammation," Current Immunology Reviews, vol. 4, no. 2, pp. 70–79, 2008.

A. V. Baranova, "Adipokine genetics: unbalanced protein secretion by human adipose tissue as a cause of the metabolic syndrome," Genetika, vol. 44, no. 10, pp. 1338–1355, 2008.